ipilimumab,nivolumab,
bms,delcath systems
['chopin']
$dcth positive initial results from chopin phase 1b trial, focus trial update and qol study presented at the 2022 asco annual meeting 
Hayden IR is a leader in driving market recognition and creating competitive advantages for micro- & small-cap companies. Disclaimer: http://t.co/i6eWYCgue2.